Ratings by Berenberg (Caroline Palomeque)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/7/2023 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Buy (N/A) |
35.22 (28.85) |
-18.09% | Details | |
| 9/7/2023 | Krystal Biotech | KRYS | New Coverage | Buy (N/A) |
124.08 (162.04) |
30.59% | Details | |
| 3/27/2023 | Halozyme Therapeutics | HALO | New Coverage | Buy (N/A) |
34.49 (38.97) |
12.99% | Details | |
| 3/16/2023 | Cerevel Therapeutics | CERE | New Coverage | Hold (N/A) |
24.45 (41.99) |
71.74% | Details | |
| 11/21/2022 | Compass Pathways | CMPS | New Coverage | Buy (N/A) |
9.96 (8.25) |
-17.17% | Details | |
| 8/30/2022 | Ascendis Pharma | ASND | New Coverage | Buy (N/A) |
90.31 (144.83) |
60.37% | Details | |
| 8/10/2022 | Ocular Therapeutix | OCUL | New Coverage | Buy (N/A) |
4.91 (5.00) |
1.83% | Details | |
| 6/23/2022 | Denali Therapeutics Inc. | DNLI | New Coverage | Buy (N/A) |
27.21 (16.11) |
-40.79% | Details | |
| 6/23/2022 | Anavex Life Sciences | AVXL | New Coverage | Buy (N/A) |
9.46 (3.68) |
-61.1% | Details | |
| 6/23/2022 | Regenxbio Inc. | RGNX | New Coverage | Buy (N/A) |
23.89 (15.90) |
-33.44% | Details |
